Abstract:Abstract Recent insights in allorecognition and graft rejection mechanisms revealed a more complex picture than originally considered, involving multiple pathways of both adaptive and innate immune response, supplied by efficient inflammatory synergies. Current pillars of transplant monitoring are serum creatinine, proteinuria, and drug blood levels, which are considered as traditional markers, due to consolidated experience, low cost, and widespread availability. The most diffuse immunological biomarkers are donor-specific antibodies, which are included in routine post-transplant monitoring in many centers, although with some reproducibility issues and interpretation difficulties. Confirmed abnormalities in these traditional biomarkers raise the suspicion for rejection and guide the indication for graft biopsy, which is still considered the gold standard for rejection monitoring. Rapidly evolving new “omic” technologies have led to the identification of several novel biomarkers, which may change the landscape of transplant monitoring should their potential be confirmed. Among them, urinary chemokines and measurement of cell-free DNA of donor origin are perhaps the most promising. However, at the moment, these approaches remain highly expensive and cost-prohibitive in most settings, with limited clinical applicability; approachable costs upon technology investments would speed their integration. In addition, transcriptomics, metabolomics, proteomics, and the study of blood and urinary extracellular vesicles have the potential for early identification of subclinical rejection with high sensitivity and specificity, good reproducibility, and for gaining predictive value in an affordable cost setting. In the near future, information derived from these new biomarkers is expected to integrate traditional tools in routine use, allowing identification of rejection prior to clinical manifestations and timely therapeutic intervention. This review will discuss traditional, novel, and invasive and non-invasive biomarkers, underlining their strengths, limitations, and present or future applications in children.

A gentler approach to monitor for heart transplant rejection

Biomarkers for Renal Transplantation: Where Are We?

Identification of Candidate Biomarkers in Peripheral Blood for Cardiac Allograft Rejection Based on Bioinformatics Analysis

Molecular Imaging of Acute Cardiac Transplant Rejection: Animal Experiments and Prospects.

Blood-based immunological monitoring after heart transplant. Current status and future prospects

Non‐invasive molecular biomarkers for monitoring solid organ transplantation: A comprehensive overview

European Society for Organ Transplantation (ESOT) Consensus Statement on the Use of Non-invasive Biomarkers for Cardiothoracic Transplant Rejection Surveillance

Preliminary Investigation of the Biomarkers of Acute Renal Transplant Rejection Using Integrated Proteomics Studies, Gene Expression Omnibus Datasets, and RNA Sequencing.

Ultrasound Molecular Imaging of Acute Cardiac Transplantation Rejection Using Nanobubbles Targeted to T Lymphocytes

Heart Transplant Rejection: From the Endomyocardial Biopsy to Gene Expression Profiling

Donor-derived Cell-free DNA—Ready for Prime Time Yet?

Outcome-Based Risk Assessment of Non-HLA Antibodies in Heart Transplantation: A Systematic Review

Molecular immune monitoring in kidney transplant rejection: a state-of-the-art review

A Novel Noninvasive Method to Detect Rejection after Heart Transplantation

Developing Renal Allograft Surveillance Strategies – Urinary Biomarkers of Cellular Rejection

Benefit And Risk Of Endomyocardial Biopsy For Heart Transplant Patients In The Contemporary Era

Progress in Noninvasive Surveillance for Acute Rejection in Pediatric Heart Transplant Recipients: A Real‐World Analysis of Donor‐Derived Cell‐Free DNA‐Based Surveillance Protocol

“Pre-Histologic” Antibody-Mediated Rejection Detected by Donor-Derived Cell-Free DNA and a Novel Tissue Gene Expression Assay: A Case Report

Detection of Subclinical Rejection in Pediatric Kidney Transplantation: Current and Future Practices

Revisiting Biomarkers of Cardiac Allograft Vasculopathy: Addressing the Achilles Heel of Heart Transplantation

Rejection markers in kidney transplantation: do new technologies help children?